Cellectis Stock Price, News & Analysis

Cellectis (Nasdaq: CLLS) announced that its upcoming general meeting on May 28, 2021, will be held in closed session due to the Covid-19 pandemic. Shareholders cannot attend physically but can vote remotely and submit questions via electronic means. The meeting will be broadcasted online. Shareholders are encouraged to use email or postal voting to participate. There are specific requirements for submitting additional agenda items or draft resolutions. Cellectis focuses on innovative CAR-T immunotherapies for various cancers and emphasizes the importance of shareholder engagement during this period.

Cellectis, a clinical-stage biopharmaceutical company, focuses on developing allogeneic CAR-T immunotherapies for cancer treatment. As of March 31, 2021, the firm reports a total of 43,039,180 shares in capital and 49,104,029 voting rights. The company aims to provide life-saving UCART product candidates to address cancers like acute myeloid leukemia and multiple myeloma. With over 21 years of expertise in gene editing, Cellectis utilizes TALEN® technology and PulseAgile electroporation to create ready-to-use gene-edited CAR T-cells.

Cellectis S.A. (NASDAQ: CLLS) has successfully completed sales of approximately $47 million in American Depositary Shares (ADS) under its ATM program initiated on March 29, 2021. A total of 2,415,630 new ADSs were issued at an average price of $19.50 each. The settlement for the new ordinary shares is expected on April 12, 2021, allowing trading on Euronext Growth and Nasdaq. This follows a shelf registration statement filed with the SEC in June 2020, which is effective for potential investors.

Cellectis S.A. (NASDAQ: CLLS) announced the filing of a prospectus supplement with the SEC related to an At-The-Market (ATM) program, allowing sales of American Depositary Shares (ADS) up to $125 million. The program aims to fund research, development, and manufacturing in the biotechnology space. Notably, this could lead to a dilution of approximately 29.74% based on existing share capital. Jefferies LLC will act as the sales agent, and the program is effective until June 2, 2023.

Cellectis, a clinical-stage biopharmaceutical company, focuses on CAR-T immunotherapies for oncology, utilizing its proprietary TALEN® gene editing technology. The company reported a total of 43,033,680 shares and 49,098,269 voting rights as of February 28, 2021. Cellectis aims to provide innovative UCART product candidates for cancers such as acute myeloid leukemia and multiple myeloma. Headquartered in Paris, Cellectis is listed on both the Nasdaq (CLLS) and Euronext Growth (ALCLS).

Cellectis reported ongoing enrollment in three Phase 1 dose-escalation trials for r/r B-ALL, r/r AML, and r/r MM, with preliminary results of the BALLI-01 study presented at ASH 2020. The company has partnered with Cytovia Therapeutics to develop TALEN® gene-edited NK cell programs and completed construction of manufacturing facilities in Paris and North Carolina. As of December 31, 2020, Cellectis had a cash position of $274 million, extending its cash runway into late 2022. A conference call is scheduled for March 5, 2021, to discuss year-end results and business updates.

Cellectis (Nasdaq: CLLS) will report its financial results for Q4 and full year 2020 on March 4, 2021, post US market close. A conference call will follow on March 5, at 8:00 AM EST. The company is developing innovative allogeneic CAR-T immunotherapies utilizing its proprietary TALEN® gene editing technology. Cellectis focuses on treating unmet needs in multiple cancers, including AML and B-ALL. The announcement comes amid ongoing advancements in its UCART product candidates and a commitment to delivering actionable therapies.

Cytovia Therapeutics and Cellectis have formed a strategic collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells. This partnership could yield up to $760 million in milestones for Cellectis. Cellectis will get single-digit royalties on sales of partnered products. Cytovia is responsible for the clinical development of these therapies, aiming for trials by 2022. The collaboration is anticipated to enhance NK cell therapies' efficacy for various cancers, capitalizing on Cellectis' gene-editing expertise to improve safety and effectiveness.

Cellectis, a clinical-stage biopharmaceutical company, is pioneering allogeneic CAR-T immunotherapies using its TALEN^® gene editing technology. As of January 31, 2021, the company has a total of 43,029,305 shares and 49,093,894 voting rights. Cellectis focuses on developing UCART product candidates to treat unmet medical needs in various cancers including acute myeloid leukemia and multiple myeloma. The company operates in Paris, New York, and Raleigh, and is listed on both Nasdaq (CLLS) and Euronext Growth (ALCLS).